Advances in development of medications for alcoholism treatment

Psychopharmacology

Volumn 139, Issue 1-2, 1998, Pages 20-33

  Litten, Raye Z ^a   Allen, John P ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Comorbidity; Craving; Depression; Medications; Pharmacotherapy

Indexed keywords

ACAMPROSATE; ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ALCOHOLISM; COMORBIDITY; DRINKING BEHAVIOR; DRUG DEVELOPMENT; HUMAN; MOOD; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; WITHDRAWAL SYNDROME;

ALCOHOL DETERRENTS; ALCOHOLISM; ANTIDEPRESSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; NALTREXONE; TAURINE;

EID: 0031687603     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050686     Document Type: Review

References (68)

1. Anton RF (1994) Medications for treating alcoholism. Alcohol Health Res World 18:265-271
2. Aubin H-J, Lehert P, Beaupere B, Parot P, Barrucand D (1995) Tolerability of the combination of acamprosate with drugs used to prevent alcohol withdrawal syndrome. Alcohol 31:25-38
3. Balldin J, Berggren U, Engel J, Eriksson M, Hard E, Soderpalm B (1994) Effect of citalopram on alcohol intake in heavy drinkers. Alcohol Clin Exp Res 18:1133-1136
4. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, Black A (1997) Fluoxetine in depressed alcoholics: a double-blind placebo-controlled trial. Arch Gen Psychiatry 54:700-705
5. Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 54:1130-1135
6. Davidson D, Swift R, Fitz E (1996) Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol Clin Exp Res 20:732-739
7. Doty P, de Wit H (1995) Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behav Pharmacol 6:386-394
8. Doty P, Kirk JM, Cramblett MJ, de Wit H (1997) Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pretreatment. Drug Alcohol Depend 47:109-116
9. Farren CK, Catapano D, O'Malley S (1997) Sertraline with naltrexone versus naltrexone alone in the treatment of alcohol dependence. Alcohol Clin Exp Res 21:64A
10. Fuller RK, Mattson ME, Allen JP, Randall CL, Anton RF, Babor TF (1994) Multisite clinical trials in alcoholism treatment research: organizational, methodological and management issues. J Stud Alcohol Suppl 12:30-37
11. Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 3:129-137
12. Gerra G, Caccavari R, Delsignore R, Bocchi R, Fertonani G, Passeri M (1992) Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Curr Ther Res 52:291-295
13. Gorelick DA, Paredes A (1992) Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 16:261-265
14. Grant BF, Harford TC, Dawson DA, Chou P, Dufour M, Pickering R (1994) Prevalence of DSM-IV alcohol abuse and dependence. Alcohol Health Res World 18:243-248
15. Hyman SE, Nestler EJ (1996) Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 153:151-162
16. Jaffe AJ, O'Malley SS, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1996) Naltrexone, relapse prevention and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 64:1044-1053
17. Kabel DI, Petty F (1996) A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment. Alcohol Clin Exp Res 20:780-784
18. King AC, Volpicelli JR, Frazer A, O'Brien CP (1997) Effects of naltrexone on subject alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129:15-22
19. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N (1995a) Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 152:391-397
20. Kranzler HR, McLellan AT, Bohn MJ (1995b) Pharmacotherapies for alcoholism: theoretical and methodological perspectives. In: Kranzler HR (ed) The pharmacology of alcohol abuse. Springer, Berlin, pp 513-537
21. Kranzler HR, Mason BJ, Pettinati HM, Anton RF (1997) Methodological issues in pharmacotherapy trials with alcoholics. In: Hertzman M, Faltner D (eds) The handbook of psychopharmacology trials. New York University, New York, pp 213-245
22. 2A receptors in alcohol drinking: preference in HAD rats is inhibited by combination treatment with naltrexone and amperozide. Alcohol 13:53-57
23. Lesch OM, Walter H (1996) Subtypes of alcoholism and their role in therapy. Alcohol Alcohol 31 [Suppl 1]:63-67
24. Lhuintre JP, Daoust M, Moore ND, Chretien P, Saligaut C, Tran G, Boismare F, Hillemand B (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1:1014-1016
25. Lhuintre JP, Moore N, Tran G, Steru L, Langrenon S, Daoust M, Parot P, Ladure P, Libert C, Boismare F, Hillemand B (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 25:613-622
26. Litten RZ, Fertig J (1996) International update: new findings on promising medications. Alcohol Clin Exp Res 20:216A-218A
27. Litten RZ, Allen J, Fertig J (1996) Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol Clin Exp Res 20:859-876
28. Littleton J (1995) Acamprosate in alcohol dependence: how does it work? Addiction 90:1179-1188
29. Madamba SG, Schweitzer P, Zieglgansberger W, Siggins GR (1996) Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro. Alcohol Clin Exp Res 20:651-658
30. Mann K, Chabac S, Lehert P, Potgieter A, Sass H (1995) Acamprosate improves treatment outcome in alcoholics: a pooled analysis of 11 randomized placebo controlled trials in 3338 patients. Presented at 34th Annual Meeting of American College of Neuropsychopharmacology, San Juan, Puerto Rico
31. Mason BJ, Kocsis JH, Ritvo EC, Cutler RB (1996) A double-blind placebo-controlled trial of desipramine in primary alcoholics stratified on the presence or absence of major depression. JAMA 275:1-7
32. McCaul ME, Wand GS, Sullivan J, Mumford G, Ouigley J (1997) β-Naltrexol level predicts alcohol relapse. Alcohol Clin Exp Res 21:32A
33. McGrath PJ, Nunes EV, Stewart JW, Goldman D Agosti V, Ocepek-Welikson K, Quitkin FM (1996) Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 53:232-240
34. Moncrieff J, Drummond DC (1997) New drug treatments for alcohol problems: a critical appraisal. Addiction 92:939-947
35. Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K (1984) Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers. Clin Pharmacol Ther 35:374-381
36. Naranjo CA, Sellers EM, Sullivan JT, Woodley DV, Kadlec K, Sykora K (1987) The serotonin uptake inhibitor citalopram attenuates ethanol intake. Clin Pharmacol Ther 41:266-274
37. Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G, Sellers EM (1989) Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther 46:301-309
38. Naranjo CA, Kadlec KE, Sanhueza P, Woodley-Remus D, Sellers EM (1990) Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 47:490-498
39. Naranjo CA, Poulos CX, Bremner KE, Lanctot KL (1992) Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. Clin Pharmacol Ther 51: 729-739
40. Naranjo CA, Bremner KE, Lanctot KL (1995) Effects of citalopram and a brief psycho-social intervention on alcohol intake, dependence and problems. Addiction 90:87-99
41. National Institute on Alcohol Abuse and Alcoholism (1992) Treatment handbook, series 3. A primer of research strategies in alcoholism treatment assessment. US Government Printing Office, Washington, D.C.
42. Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. Science 278:58-63
43. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49:881-887
44. O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B (1996a) Six month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 53:217-224
45. O'Malley SS, Jaffe AJ, Rode S, Rounsaville BJ (1996b) The experience of a "slip" among alcoholics on naltrexone versus placebo. Am J Psychiatry 153:281-283
46. O'Malley S, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (1997a) Naltrexone modification of alcohol self-administration in alcohol dependent subjects. Alcohol Clin Exp Res 21:33A
47. O'Malley SS (1997b) Naltrexone in alcohol dependence: findings related to three measures of craving in the clinic and the laboratory. Presented at NIAAA Treatment and Alcohol Craving Workshop, Washington, D.C.
48. Paille FM, Guelfi JD, Perkins AC, Royer R, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30:239-247
49. Pettinati HM (1996) Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence. Alcohol Clin Exp Res 20:23A-29A
50. Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92: 1537-1546
51. Project MATCH Research Group (1997) Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. J Stud Alcohol 58:7-29
52. Rice DP (1993) The economic cost of alcohol abuse and alcohol dependence: 1990. Alcohol Health Res World 17:10-11
53. Roberts AJ, Koob GF (1997) The neurobiology of addiction: an overview. Alcohol Health Res World 21:101-106
54. Salloum IM, Cornelius JR, Thase ME, Daley DC, Kirisci L, Spotts C (1998) Naltrexone utility in depressed alcoholics. Psychopharmacol Bull 34:111-115
55. Sass H, Soyka M, Mann K, Zieglgansberger W (1996) Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673-680
56. Schuckit MA (1996) Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 64:669-676
57. Soyka M (1997) Relapse prevention in alcoholism. Drug Ther 7: 13-327
58. Spanagel R, Putzke J, Stefferl A, Schobitz B, Zieglgansberger W (1996) Acamprosate and alcohol: II. effects on alcohol withdrawal in the rat. Eur J Pharmacol 305:45-50
59. Spanagel R, Zieglgansberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18:54-59
60. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 151:1463-1467
61. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880
62. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP (1995a) Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry 152:613-615
63. Volpicelli JR, Clay KL, Watson NT, O'Brien CP (1995b) Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 56 [suppl 7]:39-44
64. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 54:737-742
65. Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347:1438-1342
66. Williams LD, Mason BJ (1997) Combination pharmacotherapy in nalmefene nonresponders. Alcohol Clin Exp Res 21:33A
67. Yu Y-L, Fisher H, Sekowski A, Wagner GC (1997) Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats. Alcohol 14:45-48
68. Zeise ML, Kasparov S, Capogna M, Zieglgansberger W (1993) Acamprosate (calcium acetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors. Eur J Pharmacol 231:47-52